A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Gastric Cancer
Interventions
DRUG

epirubicin

50mg/m2 IV day 1

DRUG

cisplatin

60mg/m2 IV day 1

DRUG

5-fluorouracil

5-FU 200mg/m2/d IV 21 day continuous infusion Cont. infusional 5-FU 225mg/m2/day, 7 days/wk throughout entire period RT via CADD pump through PICC line

RADIATION

Radiotherapy

45Gy 25 Fractions, 5 days/week for 5 weeks

Trial Locations (19)

1871

Liverpool Hospital, Liverpool

2031

Prince of Wales Hospital, Randwick

2050

Royal Prince Alfred Hospital, Sydney

2069

Royal North Shore Hospital, Sydney

2145

Westmead Hospital, Sydney

2298

Calvary Mater Newcastle, Newcastle

2751

Nepean Cancer Care Centre, Penrith

3081

Austin Health, Melbourne

3181

Alfred Hospital, Prahran

3220

Andrew Love Cancer Care Centre, Geelong Hospital, Geelong

4029

Royal Brisbane Hospital, Herston

4102

Princess Alexandra Hospital, Woolloongabba

4224

East Coast Cancer Centre, Tugun

4710

Christchurch Hospital, Christchurch

6009

Sir Charles Gairdner Hospital, Perth

7250

Launceston General Hospital, Launceston

8006

Peter MacCallum Cancer Centre, Melbourne

Unknown

Mater QRI, Brisbane

Box Hill Hospital, Box Hill

All Listed Sponsors
collaborator

The Royal Australian and New Zealand College of Radiologists

OTHER

lead

Trans Tasman Radiation Oncology Group

OTHER

NCT00123318 - A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer | Biotech Hunter | Biotech Hunter